EU Ruling Raises New Questions For Orphan Designation
Executive Summary
An EU court has upheld a decision to revoke the orphan designation awarded to GMP-Orphan's trientine product for Wilson's disease, saying that the product no longer met the “significant benefit” criterion on the grounds of lack of availability of another drug. The case has raised questions about the level of evidence needed to justify a significant benefit.
You may also be interested in...
EMA ‘Trying Its Best’ To Offer More Early Scientific Support For Sponsors
The head of the European Medicines Agency’s scientific advisory office is hopeful that the organization’s PRIME initiative will be enshrined in EU legislation over the coming years, rather than just existing as an initiative from the agency.
EU’s ‘Significant Benefit’ Metric For Orphan Drugs Still A Thorn In Industry’s Side
Ipsen’s Bylvay is one of six medicines that the European Medicines Agency has said should be stripped of their orphan drug designation over the last three years, leading the company to criticize the agency’s approach to “significant benefit” assessments.
Univar’s Cufence Approved In EU For Wilson’s Disease, But Loses Orphan Status
Cufence, which has just been authorized for EU-wide marketing, is one of two trientine products for Wilson’s disease to lose their orphan designation.